From diagnosis to disease-specific treatment: first experience with enzyme replacement therapy for Fabry disease in North Macedonia—a case series - Report - MDSpire

From diagnosis to disease-specific treatment: first experience with enzyme replacement therapy for Fabry disease in North Macedonia—a case series

  • By

  • Vlatko Karanfilovski

  • Igor G. Nikolov

  • Pavlina Dzekova Vidimliski

  • Svetlana Krstevska Balkanov

  • Galina Severova

  • Ana Stojanoska

  • Nikola Gjorgjievski

  • May 29, 2026

  • 0 min

Share

Clinical Report: Initial Insights into Enzyme Replacement Therapy for Fabry Disease

Overview

This report presents the first national experience with enzyme replacement therapy (ERT) for Fabry disease in North Macedonia, involving two male patients post-kidney transplantation. Both patients showed significant biochemical responses, but clinical outcomes varied, particularly regarding neurological symptoms.

Background

Fabry disease is a rare X-linked lysosomal storage disorder that leads to severe multisystemic complications due to α-galactosidase A deficiency. Early initiation of ERT is crucial to mitigate irreversible organ damage.

Data Highlights

PatientERT TypeLyso-Gb3 ReductionRenal FunctionNeurological Response
1Agalsidase betaSubstantialStableMarked improvement
2Agalsidase alfaSubstantialStablePersistent fluctuations

Key Findings

  • Both patients exhibited significant reductions in Lyso-Gb3 levels post-ERT.
  • Renal graft function remained stable without proteinuria in both cases.
  • No progression of cardiac involvement was observed during the study period.
  • Patient 1 reported marked improvement in neuropathic pain and quality of life.
  • Patient 2 experienced persistent neurological symptoms despite biochemical improvements.
  • Neurological impairment in Patient 2 was linked to central and peripheral nervous system involvement.

Clinical Implications

The findings highlight the importance of early diagnosis and timely initiation of ERT in Fabry disease to optimize clinical outcomes. The variability in patient responses underscores the need for personalized treatment approaches and ongoing monitoring.

Conclusion

This case series demonstrates that ERT can effectively reduce biochemical markers of Fabry disease and stabilize organ function, although neurological outcomes may remain challenging in advanced cases.

Related Resources & Content

  1. Clinical Research in Cardiology, 2023 -- Effects of SGLT2 Inhibitors on Patients Diagnosed with Fabry Disease
  2. Journal of Gastrointestinal Surgery, 2012 -- Daily Implementation of Pancreatic Enzyme Replacement Therapy Following Pancreatic Surgery: A Survey from Northern Europe
  3. Clinical Research in Cardiology, 2023 -- Real-World Use of Tafamidis in Patients with Cardiac Transthyretin Amyloidosis in Germany
  4. Clinical Research in Cardiology, 2018 -- Assessing the CHA2DS2-VASc Score and Fabry-Specific Score for Predicting Stroke or TIA Incidence in Fabry Disease Patients Lacking Atrial Fibrillation
  5. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document, PMC, 2024
  6. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease, PMC, 2024
  7. Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-Analysis, Radiology: Cardiothoracic Imaging, 2023
  8. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document - PMC
  9. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease - PMC
  10. Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-AnalysisRadiology: Cardiothoracic Imaging

Original Source(s)

Related Content